We’re proud to showcase our partnership with EnnoDC, a clinical-stage biotechnology company pioneering innovation in immunotherapy. Based in Paris, EnnoDC focuses on developing cutting-edge dendritic cell-targeting therapies to address challenging cancers and infectious diseases. With its origins as a spin-off from the Vaccine Research Institute (VRI), EnnoDC leverages years of scientific expertise and a proprietary platform to create therapies that redefine immune system engagement.

EnnoDC’s anti-CD40 antibody platform, combined with tumor-specific or pathogenic antigens, enables precise immune activation, offering promising solutions for HPV-induced cancers, prostate cancer, HIV, and COVID-19. Their lead asset, CD40.HVac, is currently in a Phase I/II clinical trial targeting HPV16-positive oropharyngeal cancer, with other programs advancing rapidly through the pipeline.

Here’s what Benoit Rey, Head of Program Management & CMC at EnnoDC, shared about collaborating with INITS:

"We have collaborated with INITS on several occasions, including the preparation of regulatory dossiers, submissions, and interactions with EU health authorities for the approval of our clinical programs. Additionally, their CMC expertise has been invaluable for the selection of CDMOs, the development of complex manufacturing processes for biologics, and associated comparability exercises. Working with INITS has always been rigorous and relevant, combining flexibility, responsiveness, and a collaborative spirit in a consistently pleasant atmosphere."

At INITS, we take pride in providing tailored, high-quality solutions to support our clients’ most ambitious projects. Our expertise in CMC, regulatory affairs, and biomanufacturing allows us to address complex challenges and deliver impactful results.

🙏 Thank you, EnnoDC, for your trust and collaboration. We’re honored to be part of your journey and look forward to achieving more milestones together as you revolutionize immunotherapy!